CINECA IRIS Institutional Research Information System

ELISEI, ROSSELLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 24.147
EU - Europa 13.809
AS - Asia 3.895
AF - Africa 604
SA - Sud America 68
OC - Oceania 22
Continente sconosciuto - Info sul continente non disponibili 14
Totale 42.559
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 23.581
IT - Italia 3.933
DE - Germania 3.185
SE - Svezia 2.836
CN - Cina 1.778
BG - Bulgaria 1.143
GB - Regno Unito 844
SG - Singapore 767
CA - Canada 544
AT - Austria 478
TR - Turchia 442
VN - Vietnam 415
CI - Costa d'Avorio 386
UA - Ucraina 378
FI - Finlandia 306
RU - Federazione Russa 227
IN - India 197
SN - Senegal 185
HK - Hong Kong 136
CH - Svizzera 133
BE - Belgio 78
FR - Francia 56
NL - Olanda 49
CZ - Repubblica Ceca 36
BR - Brasile 32
JP - Giappone 31
GR - Grecia 26
IR - Iran 26
PL - Polonia 26
KR - Corea 24
AU - Australia 18
ID - Indonesia 16
CL - Cile 15
EU - Europa 13
IL - Israele 13
RO - Romania 12
ES - Italia 11
IE - Irlanda 11
MX - Messico 11
NG - Nigeria 10
TW - Taiwan 10
HU - Ungheria 9
RS - Serbia 9
PK - Pakistan 7
CR - Costa Rica 6
MA - Marocco 6
PH - Filippine 6
SK - Slovacchia (Repubblica Slovacca) 6
DK - Danimarca 5
MG - Madagascar 5
AR - Argentina 4
EG - Egitto 4
MY - Malesia 4
NZ - Nuova Zelanda 4
PE - Perù 4
SV - El Salvador 4
AZ - Azerbaigian 3
BO - Bolivia 3
BY - Bielorussia 3
CY - Cipro 3
EC - Ecuador 3
EE - Estonia 3
TH - Thailandia 3
VE - Venezuela 3
BH - Bahrain 2
DZ - Algeria 2
GE - Georgia 2
MN - Mongolia 2
NO - Norvegia 2
SA - Arabia Saudita 2
UY - Uruguay 2
ZA - Sudafrica 2
A1 - Anonimo 1
AE - Emirati Arabi Uniti 1
AO - Angola 1
BD - Bangladesh 1
CO - Colombia 1
GT - Guatemala 1
HR - Croazia 1
IS - Islanda 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LY - Libia 1
MT - Malta 1
MU - Mauritius 1
PT - Portogallo 1
PY - Paraguay 1
SC - Seychelles 1
Totale 42.559
Salva come PNG Salva come JPEG
Città #
Woodbridge 2.865
Fairfield 2.812
Chandler 2.124
Ann Arbor 1.965
Houston 1.872
Ashburn 1.541
Seattle 1.220
Sofia 1.142
Wilmington 1.037
Milan 994
Cambridge 967
New York 746
Beijing 685
Boardman 533
Princeton 521
Ottawa 508
Vienna 451
Lawrence 444
Jacksonville 434
Abidjan 386
Medford 360
Izmir 348
Serra 327
Des Moines 278
Singapore 274
Nanjing 261
Florence 219
Pisa 215
London 201
Dearborn 190
Dong Ket 187
Dakar 185
San Diego 165
Rome 156
Frankfurt am Main 143
Boulder 133
Bern 120
Bremen 119
Hong Kong 114
Redwood City 107
Nanchang 99
Ogden 90
Jüchen 74
Brussels 73
Washington 71
Kunming 69
Munich 65
Los Angeles 64
Düsseldorf 59
Tianjin 59
Lancaster 57
Changsha 56
Kocaeli 54
Hebei 53
Nürnberg 52
Redmond 51
Shenyang 50
Jiaxing 49
Norwalk 48
Dallas 47
Shanghai 44
Naples 42
Chicago 39
Falls Church 36
Hefei 36
Detroit 32
Hangzhou 31
Zhengzhou 30
Phoenix 28
Grafing 27
Pune 27
Bologna 26
Brno 26
Jinan 26
Vicopisano 25
Guangzhou 24
Istanbul 22
Hyderabad 21
Verona 20
Sacile 19
Auburn Hills 18
Chengdu 17
Indiana 16
Orange 16
Marseille 15
Napoli 15
San Francisco 15
Poltava 14
Tappahannock 14
Tokyo 14
Toronto 14
Trieste 14
Turin 14
Wuhan 14
Bengaluru 13
Ningbo 13
Genoa 12
Lucca 12
Mumbai 12
Palermo 12
Totale 29.454
Salva come PNG Salva come JPEG
Nome #
I CARCINOMI PAPILLARI E MIDOLLARI DELLA TIROIDE PRESENTI CONTEMPORANEAMENTE HANNO ORIGINE GENETICA INDIPENDENTE 791
Surgical treatment of low- and intermediate-risk papillary thyroid cancer with minimally invasive video-assisted thyroidectomy 259
null 259
L’ANALISI GENETICA DI CARCINOMI PAPILLARI E MIDOLLARI DELLA TIROIDE PRESENTI CONTEMPORANEAMENTE RIVELA LA LORO NATURA CASUALE 250
ALL-TRANS RETINOIC ACID TREATMENT INHIBITS THE GROWTH OF RARb mRNA EXPRESSING THYROID CANCER CELL LINES BUT DOES NOT RE-INDUCE THE EXPRESSION OF THYROID SPECIFIC GENES 194
Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line. 193
Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. 187
Polymorphisms within base and nucleotide excision repair pathways and risk of differentiated thyroid carcinoma 185
Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: A 10 years follow up study 183
The presence of a tall cells>10% in a classical variant of papillary thyroid carcinoma (CV-PTC) makes its aggressiveness similar to that of tall cell variant (TCV-PTC) 179
Ciglitazone induces cell growth inhibition in a medullary thyroid carcinoma cell line (TT) likely by an increase of PPARgamma expression 175
T cell responses to orbital antigens in thyroid-associated ophthalmopathy. 174
Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients 172
In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer 171
Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland 167
Identification of a novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition 162
Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life 162
Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line 161
Incidental versus clinically evident thyroid cancer: A 5-year follow-up study 161
null 160
Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies 159
Risk of Differentiated Thyroid Carcinoma and Polymorphisms within the Susceptibility Cancer Region 8q24 159
Circulating neuron-specific enolase in medullary thyroid cancer. 158
Thyroid carcinoma in thyrotoxic patients treated by surgery. 157
null 157
V804M RET MUTATION AND VANDETANIB RESPONSE IN METASTATIC MEDULLARY THYROID CANCER 153
Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: Clinical implications derived from the first prospective randomized controlled single institution study 152
Targeted Therapy in Thyroid Cancer: State of the Art 152
Studies with recombinant autoepitopes of thyroid peroxidase: evidence suggesting an epitope shared between the thyroid and the gastric parietal cell. 150
Routine serum calcitonin measurement in the evaluation of thyroid nodules 150
All-trans Retinoic Acid treatment inhibits the growth of RARb mRNA expressing thyroid cancer cell lines but does not re-induce the expression of thyroid specific genes 149
A new germline RET mutation apparently devoid of transforming activity serendipitously discovered in a patient with atrophic autoimmune thyroiditis and primary ovarian failure 148
Advances in the follow-up of differentiated or medullary thyroid cancer. 148
CLINICAL IMPACT OF RET GENETIC SCREENING IN THE MANAGEMENT OF MEDULLARY THYROID CARCINOMA (MTC) PATIENTS: 20 YEARS OF EXPERIENCE 148
Changing Trend of Thyroglobulin Antibodies in Patients with Differentiated Thyroid Cancer Treated with Total Thyroidectomy Without ¹³¹I Ablation 147
null 146
Medullary thyroid cancer treated with vandetanib: predictors of longer and durable response 146
Chromosome 10 and RET gene copy number alterations in hereditary and sporadic Medullary Thyroid Carcinoma. 145
A complex MEN2 syndrome, a mixture of 2B and 2A, associated with a new RET germiline deletion. 144
Identification of two distinct molecular subtypes by digital RNA counting of "non-invasive follicular tumour with papillary-like nuclear features (NIFTP)" 144
Treatment of advanced thyroid cancer with targeted therapies: Ten years of experience 143
Motesanib diphosphate in progressive differentiated thyroid cancer 142
Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal 141
BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: A 15-year median follow-up study 141
Thyroid cancer in children and adolescents. 140
Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. 140
RET/PTC rearrangements in Belarus, Ukrainian and Russian pos Chernobyl thyroid tumors 140
Novel genome-wide association study-based candidate loci for differentiated thyroid cancer risk. 139
Use of low-dose radioiodine ablation for Graves' orbitopathy: results of a pilot, perspective study in a small series of patients 138
null 137
Association between CYP2E1 polymorphisms and risk of differentiated thyroid carcinoma 137
Prevalence of papillary thyroid cancer (PTC) in patients affected by medullary thyroid cancer (MTC) 136
A patient with MEN1 and end‑stage chronic kidney disease due to Alport syndrome: Decision making on the eligibility of transplantation 136
Serum bone Gla-protein (osteocalcin) in patients with bone metastases from thyroid cancer 135
RET point mutations in Thyroid Carcinoma 135
Hypertension, nausea, anorexia and weight loss were significantly associated with better progression-free survival in patients with radioiodine-Refractory Differentiated Thyroid Carcinoma treated with Lenvatinib 135
RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC) 135
BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas 134
Thyroglobulin Antibodies (TgAb) Titer Spontaneously Decrease Until The Negativization Or Stabilization In Most Of Cases Of Papillary Thyroid Microcarcinoma (mPTC) Treated With Total Thyroidectomy But Not Ablated With 131I 134
European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium 133
Clinical, pathological and genetic features of anaplastic and poorly differentiated thyroid cancer: A single institute experience 133
Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. 131
Modifications in the Papillary Thyroid Cancer Gene Profile Over the Last 15 Years. 131
mRNA and miRNA expression profiling of follicular variant of papillary thyroid carcinoma with and without distant metastases 131
CDKN1B V109G polymorphism a new prognostic factor in sporadic medullary thyroid carcinoma 130
Re-differentiation of thyroid carcinoma cell lines treated with 5-Aza-2'-deoxycytidine and retinoic acid 128
Medullary thyroid carcinoma (MTC) and RET proto-oncogene: Mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic form. 128
Genome-wide association study on differentiated thyroid cancer. 128
Association between BRAF V600E mutation and recurrence of papillary thyroid cancer 128
Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer 128
Evidences that the polymorphism Pro-282-Ala within the tumor suppressor gene WWOX is a new risk factor for differentiated thyroid carcinoma 128
Lack of evidence supporting the presence of mRNA for the thyrotropin receptor in extra-ocular muscle. 126
Next generation sequencing revealed RET or RAS mutation in medullary thyroid cancer that were negative at sanger sequencing 126
Nuove indicazioni all’impiego del TSH umano ricombinante (rhTSH) e basse attività di 131I nella radioablazione del residuo tiroideo post-chirurgico. 125
A comprehensive meta-analysis of case-control association studies to evaluate polymorphisms associated with the risk of differentiated thyroid carcinoma 125
Contralateral papillary thyroid cancer is frequent at completion thyroidectomy with no difference in low- and high-risk patients 124
Lenvatinib therapy in progressive, radioiodine-refractory, differentiated thyroid carcinoma: analysis of 74 cases followed in a single centre 124
BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer 123
Modifications in the Papillary Thyroid Cancer Gene Profile Over the Last 15 Years. 123
Muscle autoantigens in thyroid associated ophthalmopathy: the limits of molecular genetics. 122
New and old knowledge on differentiated thyroid cancer epidemiology and risk factors. 122
Anaplastic thyroid cancer therapy: dream or reality? 122
TPO genetic variants and risk of differentiated thyroid carcinoma in two European populations. 122
null 122
Lung recurrence of papillary thyroid cancer diagnosed with antithyroglobulin antibodies after 10 years from initial treatment. 122
Ret Genetic Screening in Patients with Medullary Thyroid Cancer and Their Relatives: Experience with 807 Individuals at One Center 121
Il carcinoma tiroideo: nuove prospettive terapeutiche. 121
Demonstration of the existence of the alternatively spliced form of thyroid peroxidase in normal thyroid. 120
Thyroid nodule and differentiated thyroid cancer management in pregnancy. An Italian Association of Clinical Endocrinologists (AME) and Italian Thyroid Association (AIT) Joint Statement for Clinical Practice 120
Thyroid consequences of the Chernobyl nuclear accident. 120
KIF5B/RET Rearrangement in a Carcinoma of the Thyroid Gland: A Case Report of a Fatal Disease 120
Interventional bronchoscopy in the treatment of tracheal obstruction secondary to advanced thyroid cancer 119
Inherited variants in genes somatically mutated in thyroid cancer 119
Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma 119
Post-surgical follow-up of differentiated thyroid cancer. 118
, Descrizione della prima mutazione omozigote germinale di RET (Ala883->Thr) che non determina l'insorgenza del carcinoma midollare della tiroide in condizioni di eterozigosi 118
Successo terapeutico di Lenvatinib in seconda linea in un caso di carcinoma follicolare della tiroide avanzato 118
Retinoic acid receptor beta2 re-expression and growth inhibition in thyroid carcinoma cell lines after 5-aza-2'-deoxycytidine treatment 117
Cytotoxic effects of carboplatinum and epirubicin in the setting of an elevated serum thyrotropin for advanced poorly differentiated thyroid cancer 117
Thyroid autoantibodies and thyroid function in subjects exposed to Chernobyl fallout during childhood: evidence for a transient radiation-induced elevation of serum thyroid antibodies without an increase in thyroid autoimmune disease. 117
Totale 15.044
Salva come PNG Salva come JPEG
Categoria #
all - tutte 121.000
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 121.000
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20206.929 0 0 540 549 870 942 904 637 773 647 899 168
2020/20213.691 386 244 314 147 292 247 281 320 340 316 244 560
2021/20225.321 124 233 126 379 1.098 697 178 241 285 218 339 1.403
2022/20237.689 971 1.124 611 611 766 910 137 614 1.324 73 456 92
2023/20245.349 584 554 636 380 711 926 287 173 141 115 265 577
2024/2025831 169 662 0 0 0 0 0 0 0 0 0 0
Totale 43.472